GLP-1 medications have transformed the weight loss landscape. But with multiple options now available, patients are understandably confused about which medication is right for them. Here's a clear comparison.
The three main options
Ozempic (semaglutide) was originally FDA-approved for type 2 diabetes but is widely prescribed off-label for weight loss. It's the most commonly known GLP-1 medication thanks to significant media coverage.
Wegovy (semaglutide) contains the same active ingredient as Ozempic but at a higher dose, and is FDA-approved specifically for weight management. It's the "official" weight loss version of semaglutide.
Mounjaro (tirzepatide) targets two hormones — GLP-1 and GIP — rather than just GLP-1. Clinical trials show it produces greater average weight loss than semaglutide. Its weight-loss version, Zepbound, was FDA-approved in late 2023.
How they compare on weight loss
Semaglutide (Ozempic/Wegovy): Clinical trials show average weight loss of 12–15% of body weight over 68 weeks. That's about 30–40 pounds for a 250-pound patient.
Tirzepatide (Mounjaro/Zepbound): Clinical trials show average weight loss of 15–22% of body weight, with some patients losing over 25%. The dual-hormone mechanism appears to be more effective.
Cost comparison
Without insurance, monthly costs range from $900 to $1,400 for brand-name versions. Compounded semaglutide — available through compounding pharmacies — costs $250–$500 per month. Insurance coverage is improving but still inconsistent.
The importance of medical supervision
GLP-1 medications are powerful tools, but they work best as part of a comprehensive medical weight loss program that includes dietary guidance, activity recommendations, and regular monitoring. Find a provider who offers the full program, not just the prescription.
Looking for a wellness provider?